RIGL

Rigel Pharmaceuticals, Inc. (RIGL) | Rumor.io

Rigel Pharmaceuticals

RIGL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,751

Bullish sentiment (50-day avg)91%

Price to earnings ratio2.85

Market capitalization922M

Earnings per share17.3

Dividend yield (TTM)—

Revenue (annual)294.3M

Net income (annual)367M

Social

What share of all stock conversation is about RIGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Aug 26

Rigel Pharmaceuticals' earnings are expected to increase due to royalties from Veppanu, with Pfizer receiving 12.5% of sales and having over 5 billion shares in their float.
Short interest in Rigel is climbing, and some analysts believe that the short positions will be squeezed as the stock continues to climb.
Rigel's stock has jumped 15%, and some analysts are predicting a further 40% upside, with Veppanu's sales and royalties expected to drive earnings growth.

Generated by AI

Sentiment

Of the messages about RIGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	71.43% -28.57	88.24% -4.31	92.11% +4.34
Bearish	0%	28.57% +28.57	11.76% +4.31	7.89% -4.34

Bullish· Aug 5

The company has a strong track record of sales growth, with analysts impressed by its future developments, and the author is confident that it will move up in the coming weeks and months.
The author believes that the shorts are trapped, and the company will break through resistance levels, potentially reaching $50 and providing easy money for those who hold through dips.
The company has a strong team in place to roll out its best medical product yet, and its execution and expansion are good, making it a good buy even if the price is not currently favorable.

Bearish· May 7

The stock has been manipulated for four years, with abnormal price movements that are potentially criminal in nature.
The large number of small trades marching the stock down from its high may be intended to evoke emotions and drive down the price.
The stock's price has been artificially suppressed, with investors waiting to see how low it will go before buying, as evidenced by low volume and a legitimate PE ratio that is not being reflected in the current price.

Generated by AI

Topics

Of the messages about RIGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	68.42%	54.14%
Technical Analysis	—	0%	21.05%	13.56%
Earnings	—	0%	10.53%	4.67%
Analysts	—	0%	0%	13.41%
Controversies	—	0%	0%	6.53%
Macro	—	0%	0%	7.68%

Earnings· Mar 7

Rigel Pharmaceuticals (RIGL) reported Q4 EPS of $0.01, beating the estimate of $(0.11) by 109.09%.
Q4 sales of $51.30 million beat the estimate of $27.97 million by 83.41%, a 151.36% increase over the same period last year.
RIGL's Q4 earnings were driven by strong quarterly growth, with the company expecting further pipeline expansion and transformative P3 results later in the year.

Analysts· Dec 2

Analyst Yigal Nochomovitz from Citigroup upgraded Rigel Pharmaceuticals to Buy with a price target of $15, suggesting 800% upside.
Citigroup analyst Yigal Nochomovitz and BMO Capital analyst Gary Nachman both maintain a Buy rating on Rigel Pharmaceuticals, with H.C. Wainwright analyst Joseph Pantginis also reiterating a Buy rating.
Citigroup's upgrade of Rigel Pharmaceuticals to Buy was driven by the earlier-than-expected approval of a leukemia treatment, with the firm setting a price target of $2.

Announcements· May 12

Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU for ER+ breast cancer.
The deal is worth $70 million upfront, with potential milestones of up to $320 million and royalties in the mid-teens to mid-twenties.
The partnership is expected to contribute to Rigel's growth as a commercial oncology company, addressing concerns about the company's future patent cliff after 2032.

Technical Analysis· Mar 8

$RIGL needs to hold support at 1.60, which is the intersection of the 20 and 50-day SMAs.
The stock is expected to face resistance at 2.10 before potentially breaking out to 2.5 or higher.
The monthly Heiken-Ashi chart shows potential for a move up on the V-pattern, with the CEO's recent purchase of 1M shares at the bottom indicating bullish sentiment.

Generated by AI

Community

Of the messages about RIGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	77.78%	85.71%	88.07%	76.28%
Newcomers	22.22%	14.29%	11.93%	23.72%

Regulars· Aug 6

The regulars are considering the possibility of a strategic transaction, such as a merger or joint venture, due to the company's strong earnings reports and high short interest.
The hiring of additional staff by Rigel Pharmaceuticals suggests that the company is preparing for an expansion of its commercial operations, which could have a significant impact on the stock.
The regulars are waiting for the first update showing strong prescriptions, patient starts, or sales of Rigel's VEPPANU product, which could be a major catalyst for the stock.

Newcomers· Mar 3

The newcomer is focused on the strong Q4 revenue of $69.8M and FY25 revenue of $294.3M for Rigel Pharmaceuticals, with a notable increase in net product sales and cash reserves.
The newcomer highlights the record-breaking 2025 results for Rigel Pharmaceuticals, with a net income of $367M, driven by a non-cash tax benefit, and notes a significant increase in net product sales.
The newcomer expresses concern about the decelerating future of Rigel Pharmaceuticals, with a sharp deceleration in 2026 guidance, despite a strong 2025 with record top-line and illusionary bottom-line performance.

Generated by AI

Also Discussed

Investors talking about RIGL also mention

#	Name	Attention
1	PRTK - Paratek Pharmaceuticals, Inc.	——
2	Geron CorporationGERN	0%0
3	Verastem Inc.VSTM	0%0
4	FOLD - Amicus Therapeutics, Inc.	——
5	DRRX - DURECT Corporation	——
6	IMGN - ImmunoGen, Inc.	——
7	BPMC - Blueprint Medicines Corporation	——
8	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
9	PTC Therapeutics, Inc.PTCT	0%new
10	CTIC - CTI BioPharma Corp.	——

Rigel Pharmaceuticals, Inc.

Healthcare
Biotechnology

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer. The company’s current portfolio centers on commercial products and clinical-stage programs that address blood cancers and related immune-driven conditions, with an emphasis on targeted small-molecule medicines. Its marketed therapies support treatment in specialized physician markets, including hematology and oncology, while its research pipeline includes additional candidates designed to modulate key signaling pathways involved in disease progression. Rigel Pharmaceuticals also works through collaboration and licensing activities that support the development and commercialization of its products. Headquartered in South San Francisco, California, and founded in 1996, Rigel Pharmaceuticals plays a focused role in the biopharmaceutical market by supplying therapies for complex conditions with limited treatment options.

Website

Location

611 Gateway Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about RIGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Aug 26

Rigel Pharmaceuticals' earnings are expected to increase due to royalties from Veppanu, with Pfizer receiving 12.5% of sales and having over 5 billion shares in their float.
Short interest in Rigel is climbing, and some analysts believe that the short positions will be squeezed as the stock continues to climb.
Rigel's stock has jumped 15%, and some analysts are predicting a further 40% upside, with Veppanu's sales and royalties expected to drive earnings growth.

Generated by AI

Sentiment

Of the messages about RIGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	71.43% -28.57	88.24% -4.31	92.11% +4.34
Bearish	0%	28.57% +28.57	11.76% +4.31	7.89% -4.34

Bullish· Aug 5

The company has a strong track record of sales growth, with analysts impressed by its future developments, and the author is confident that it will move up in the coming weeks and months.
The author believes that the shorts are trapped, and the company will break through resistance levels, potentially reaching $50 and providing easy money for those who hold through dips.
The company has a strong team in place to roll out its best medical product yet, and its execution and expansion are good, making it a good buy even if the price is not currently favorable.

Bearish· May 7

The stock has been manipulated for four years, with abnormal price movements that are potentially criminal in nature.
The large number of small trades marching the stock down from its high may be intended to evoke emotions and drive down the price.
The stock's price has been artificially suppressed, with investors waiting to see how low it will go before buying, as evidenced by low volume and a legitimate PE ratio that is not being reflected in the current price.

Generated by AI

Topics

Of the messages about RIGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	68.42%	54.14%
Technical Analysis	—	0%	21.05%	13.56%
Earnings	—	0%	10.53%	4.67%
Analysts	—	0%	0%	13.41%
Controversies	—	0%	0%	6.53%
Macro	—	0%	0%	7.68%

Earnings· Mar 7

Rigel Pharmaceuticals (RIGL) reported Q4 EPS of $0.01, beating the estimate of $(0.11) by 109.09%.
Q4 sales of $51.30 million beat the estimate of $27.97 million by 83.41%, a 151.36% increase over the same period last year.
RIGL's Q4 earnings were driven by strong quarterly growth, with the company expecting further pipeline expansion and transformative P3 results later in the year.

Analysts· Dec 2

Analyst Yigal Nochomovitz from Citigroup upgraded Rigel Pharmaceuticals to Buy with a price target of $15, suggesting 800% upside.
Citigroup analyst Yigal Nochomovitz and BMO Capital analyst Gary Nachman both maintain a Buy rating on Rigel Pharmaceuticals, with H.C. Wainwright analyst Joseph Pantginis also reiterating a Buy rating.
Citigroup's upgrade of Rigel Pharmaceuticals to Buy was driven by the earlier-than-expected approval of a leukemia treatment, with the firm setting a price target of $2.

Announcements· May 12

Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU for ER+ breast cancer.
The deal is worth $70 million upfront, with potential milestones of up to $320 million and royalties in the mid-teens to mid-twenties.
The partnership is expected to contribute to Rigel's growth as a commercial oncology company, addressing concerns about the company's future patent cliff after 2032.

Technical Analysis· Mar 8

$RIGL needs to hold support at 1.60, which is the intersection of the 20 and 50-day SMAs.
The stock is expected to face resistance at 2.10 before potentially breaking out to 2.5 or higher.
The monthly Heiken-Ashi chart shows potential for a move up on the V-pattern, with the CEO's recent purchase of 1M shares at the bottom indicating bullish sentiment.

Generated by AI

Community

Of the messages about RIGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	77.78%	85.71%	88.07%	76.28%
Newcomers	22.22%	14.29%	11.93%	23.72%

Regulars· Aug 6

The regulars are considering the possibility of a strategic transaction, such as a merger or joint venture, due to the company's strong earnings reports and high short interest.
The hiring of additional staff by Rigel Pharmaceuticals suggests that the company is preparing for an expansion of its commercial operations, which could have a significant impact on the stock.
The regulars are waiting for the first update showing strong prescriptions, patient starts, or sales of Rigel's VEPPANU product, which could be a major catalyst for the stock.

Newcomers· Mar 3

The newcomer is focused on the strong Q4 revenue of $69.8M and FY25 revenue of $294.3M for Rigel Pharmaceuticals, with a notable increase in net product sales and cash reserves.
The newcomer highlights the record-breaking 2025 results for Rigel Pharmaceuticals, with a net income of $367M, driven by a non-cash tax benefit, and notes a significant increase in net product sales.
The newcomer expresses concern about the decelerating future of Rigel Pharmaceuticals, with a sharp deceleration in 2026 guidance, despite a strong 2025 with record top-line and illusionary bottom-line performance.

Generated by AI

Rigel Pharmaceuticals

Social

Aug 26

Sentiment

Bullish· Aug 5

Bearish· May 7

Topics

Earnings· Mar 7

Analysts· Dec 2

Announcements· May 12

Technical Analysis· Mar 8

Community

Regulars· Aug 6

Newcomers· Mar 3

Also Discussed

Rigel Pharmaceuticals, Inc.

Company Information

Location

Also Discussed

Social

Aug 26

Sentiment

Bullish· Aug 5

Bearish· May 7

Topics

Earnings· Mar 7

Analysts· Dec 2

Announcements· May 12

Technical Analysis· Mar 8

Community

Regulars· Aug 6

Newcomers· Mar 3